Newborn Screening Quality Assurance Program Newborn Screening Quality Assurance Program Comparison of Less Sensitive HIV Incidence Tests for the Serological.

Slides:

Advertisements

Similar presentations

Combined Rapid and HIV RNA Testing in a Public STD Clinic: San Francisco, Jeffrey D. Klausner, Susan Philip, Katherine Ahrens, Giuliano Nieri,

Advertisements

Development of an oral fluid assay capable of differentiating recent from established HIV infection Niel Constantine 1, Ligia Peralta 1, Anne Sill 2, Kristen.

Satellite meeting on the STARHS HIV diagnostic assay in association with the 15th International AIDS Conference July 2004, Bangkok, Thailand Robert S.

IDENTIFICATION OF FACTORS IMPACTING THE DETERMINATION OF HIV INCIDENCE IN NON-RESEARCH-BASED, CLINICAL POPULATIONS Sill, A.M. 1 ; Constantine, N.T. 2 ;

Unit 6 Diagnosis & Follow-up of HIV Infection

HIV-1/HIV-2 PLUS O To detect HIV Antibody Groups M & O Genetic Systems™ HIV-1/HIV-2 PLUS O EIA   HIV Subtypes and Variants   Description of HIV-1/HIV-2.

Performance of Bio-Rad Genetic Systems HIV-1/HIV-2 Plus O EIA Followed by Multispot or OraQuick Advance in a Dual Immunoassay HIV Testing Strategy Laura.

Comparative Performance of Dual 3rd Generation Immunoassays as a Potential Laboratory-Based HIV-1/2 Testing Strategy. B. Bennett, S. Fordan, O. David,

CHER Trial: Early Antiretroviral Therapy and Mortality Among HIV- Infected Infants New England J Med 2008;359 (21):

Utilizing a Non-Commercial Real- Time PCR to Detect HIV-1 RNA in HIV Antibody Negative Diagnostic Sera Submitted to The Maryland Public Health Laboratory.

Using longitudinal, population-based HIV surveillance to measure the real-world impacts of ART scale-up in KwaZulu- Natal, South Africa Frank Tanser Presentation.

Impact of Age and Race on New HIV Infections among Men who have Sex with Men in Los Angeles County Shoshanna Nakelsky, MPH Division of HIV and.

Abstract Results continued Reference 1 McDonald LC, Coignard B, Dubberke E, et al. Recommendations for Surveillance of Clostridium difficile-Associated.

Use of dried blood spots (DBS) or dried serum/plasma spots (DSS/DPS) to detect recent HIV-1 seroconversion by the BED-CEIA Bharat Parekh, PhD Centers for.

Improved Reflexive Testing Algorithm for Hepatitis C Infection Using Signal-to-Cutoff Ratios of a Hepatitis C Virus Antibody Assay K.K.Y. Lai, M. Jin,

12/6/07 v.3CDC 2007 HIV Diagnostic Conference1 Diagnosis of HIV-1 Infection in Phase I & II HIV Vaccine Trials RW Coombs 1, J Dragavon 1, B Metch 2, CJ.

An Introduction to HIV Incidence Surveillance (HIS) in California California Department of Public Health Office of AIDS.

Use of avidity reagent. Panbio Buffered Avidity Reagent Mild protein-denaturing solution that may be useful in differentiating recent infections from.

Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.

C. difficile Lab ID Reporting in NHSN Stanley Ostrawski RN, MS, MT(ASCP), CIC Infection Preventionist Consultant.

A Simple and Inexpensive Particle Agglutination Assay for Identifying Recent HIV Infection Niel Constantine 1, Li Hong 2, Kristen Kreisel 1, Anne Sill.

Primary HIV Infection: the CDC study Pragna Patel, MD MPH Medical Epidemiologist Behavioral and Clinical Surveillance Branch DHAP, CDC February 28, 2005.

Vironostika® HIV-1 Plus O Microelisa System

Testing algorithms used at Bureau of Labs Michigan Department of Community Health Information on testing algorithms for processing and reporting serological.

Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.

Is Nucleic Acid Testing for Organ Donors the ‘Right’ Choice? Reference: Humara A, Morrisb M, Blumbergc R, et al. Nucleic acid testing (NAT) of organ donors:

Pre-amble: The promises and pitfalls of using assays for recent infection to estimate HIV incidence Denis Nash, PhD, MPH Associate Professor Epidemiology.

Alere TM HIV Combo Yuko Tamanoue, Product Development Department.

California Department of Public Health Office of AIDS Guide for Health Department Surveillance Staff Collecting Data on the new Testing and Treatment History.

Enhancing HIV/AIDS Surveillance in California California Department of Public Health Office of AIDS Guide for Health Care Providers.

Evaluation of Commercially Available HIV Assays to Address Alternative Screening/Diagnostic Algorithms S. Michele Owen, Ph.D. Laboratory Branch Division.

Kelley Bemis Use of automated testing in syphilis diagnosis and its impact on surveillance – Connecticut, 2010 CDC/CSTE Applied Epidemiology Fellowship.

Tests for Recent Infection and CDC’s Plans for the Detuned IND Bernard M. Branson, M.D. Centers for Disease Control and Prevention.

Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIV/AIDS, Viral Hepatitis,

CLINICAL TRIAL OF THE HEMA-STRIP HIV RAPID TEST USING FINGERSTICK BLOOD, WHOLE BLOOD, PLASMA, AND SERUM Niel T. Constantine 1, Dan Bigg 2, Daniel Cohen.

Figure 1 A Case Series of Discordant Laboratory Results with Statewide Rapid HIV Testing in New Jersey Eugene G Martin, PhD 1, Gratian Salaru, MD 1, Sindy.

HIV/AIDS is preventable and treatable, but is incurable.

IN THE NAME OF GOD Blood Safety S. AMINI KAFI ABAD CLINICAL AND ANATOMICAL PATHOLOGIST IRANIAN BLOOD TRANSFUSION ORGANIZATION(IBTO) RESEARCH CENTER June.

RESULTS Rapid testing started at one publicly funded counseling and testing site in New Jersey on November 1, Through December 31, 2004, 48 sites.

Development of a detuned oral assay for recent HIV infection F. Priddy 1, P. Phelan 1, P. Tambe 1,2, C. del Rio 1 1 Emory University School of Medicine,

Reducing HIV and HCV Transmission among Injecting Drug Users in New York.

ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES XVIII International AIDS Conference, July , Vienna Austria Recent Trends in estimated HIV-1.

Alliance Discussion with Office of AIDS: November HIV/AIDS Surveillance Surveillance overview HIV Incidence Surveillance Second Surveillance Stakeholder.

Results and Discussion Results from testing 78 samples from 58 HIV-1 positive deferred plasma donors by 12 tests employing 10 different methods are illustrated.

HIV diagnosis (general) ImmunoassaysNAT (PCR)

Bias in estimates of HIV incidence based on the detuned assay: A proposed solution Robert S Remis, Robert WH Palmer, Janet M Raboud Department of Public.

Using the detuned assay to determine HIV incidence in Ontario: Results and methodologic perspectives Robert S. Remis, Carol Major, Carol Swantee, Margaret.

HIV INCIDENCE SURVEILLANCE (HIS) PROGRAM California Department of Public Health Office of AIDS Surveillance Section.

This presentation is made available through a Creative Commons Attribution- Noncommercial license. Details of the license and permitted uses are available.

The Use of Pooled Viral Load Testing to Identify Antiretroviral Treatment Failure Davey Smith 1, Susanne May 2, Josué Perez-Santiago 1, Matthew Strain.

Further information: Performance of HIV Enzyme-Immunoassays on Dried Blood Spots for Quality Control of HIV Testing Dennis Olara 1,

CDC Guidelines for Use of QuantiFERON ® -TB Gold Test Philip LoBue, MD Centers for Disease Control and Prevention Division of Tuberculosis Elimination.

Trends in HIV incidence in Ontario based on the detuned assay: Update to December 2002 Robert S. Remis, Carol Major, Carol Swantee, Margaret Fearon, Robert.

Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIVAIDS, Viral Hepatitis, STD,

HIV/AIDS is preventable and treatable, but is incurable.

National Prevalence of Transmitted HIV Drug Resistance in Swaziland in 2011 R. Suzanne Beard, Ph.D. Abstract/poster: TUPDC0103.

Uganda Virus Research Institute The contribution of HIV incidence and antiretroviral (ART) accessibility to HIV prevalence trends among adults in rural.

THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS Yield and impact of repeated screening for tuberculosis and isoniazid preventive therapy among patients.

BioPlex 2200 HIV Ag-Ab Assay

Serologic markers and molecular epidemiology of HBV from an HIV infected cohort from Cameroon Tshifhiwa Magoro 1, Emmaculate Nongpang 2, Lufuno Mavhandu.

NAAT identified chlamydial infections: Enhanced sensitivity, reduced transmissibility? Presenter: Maria Villarroel, MA Authors: Maria A. Villarroel, MA.

HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.

Copyright © 2010 American Medical Association. All rights reserved.

Seroprevalence, prevalence, type and factors associated with HPV infection at multiple sites in young HIV-positive MSM On behalf of the HPV MAPS Research.

TUPEB018 Field evaluation of rapid HIV serologic tests for screening HIV-1/2 infection using serum samples from Rakai Cohort, Uganda. S.C. Kagulire, P.D.

DEPARTMENT OF PAEDIATRICS, THE QUEEN ELIZABETH HOSPITAL,

California Clinical Laboratory Association

CDC Guidelines for Use of QuantiFERON®-TB Gold Test

Kaplan-Meier survival curve for all catheterisations.

MSM Attending STD Clinics HIV Testing More Frequently: Implications for HIV Prevention and Surveillance D Helms1, H Weinstock1, K Mahle1, A Shahkolahi1,2,

Presentation transcript:

Newborn Screening Quality Assurance Program Newborn Screening Quality Assurance Program Comparison of Less Sensitive HIV Incidence Tests for the Serological Testing Algorithm for Recent HIV Seroconversion (STARHS) J. Schiffer, B. Byers, B. Branson, S. Ethridge, K. Delaney, J. Mei Comparison of Less Sensitive HIV Incidence Tests for the Serological Testing Algorithm for Recent HIV Seroconversion (STARHS) J. Schiffer, B. Byers, B. Branson, S. Ethridge, K. Delaney, J. Mei Centers for Disease Control and Prevention Atlanta, GA Centers for Disease Control and Prevention Atlanta, GA 30341

Background STARHS uses a modified protocol of the bioMerieux Vironostika HIV-1 MicroElisa system (V-LS)- To be replaced in 2005 We investigated the comparability of the replacement test, Vironostika HIV-1 Plus O (VPlusO-LS) Longitudinal specimens from the HIVNET Infected Participant Cohort (IPC) were tested using both kits

Methods IPC specimen set 1009 specimens from 105 recent seroconverters Known dates of last negative and first positive HIV test Tested in triplicate on both assays

Methods Window Period Calculation –324 specimens from 59 patients 3 or more specimens collected before starting antiretroviral therapy (Mean length of follow up 504 Days) Mean window period definition –Number of days between detection of HIV antibody with a standard EIA and a threshold SOD of 1.0 with the LS-EIA

Results V-LS classified 459 samples as incident (SOD<1), and VplusO classified 472 as incident (90.2% concordance). Specimen SOD’s diminished after patients started antiretroviral therapy.

V-LS vs. VplusO-LS Sqrt SOD y = 0.996x R 2 = V-LS Sqrt SOD VplusO-LS Sqrt SOD

Table 1: Window Period and Confidence Intervals for LS Tests Vironostika-LSVironostika Plus O-LS SOD Cutoff Window Period 95% Confidence Interval N (Patients, Samples) Window Period 95% Confidence Interval N (Patients, Samples) , , , , , , , , , , 324

Two-Year Rule SODs tended to plateau or decline after 2 years from last negative specimen. May result in longer window periods New window periods calculated excluding specimens collected after 2 years from last negative test

Window Period (SOD = 1) 95% Confidence Interval N (Patients, Samples) Vironostika-LS (IPC, 2 year cutoff) , 290 Vironostika Plus O-LS (IPC, 2 year cutoff) , 294 Vironostika-LS (SFMHS, 2003) , 227 Table 2 Window periods and confidence intervals for V-LS and VplusO-LS calculated with the two year cutoff rule applied to the IPC sample set. The V-LS window period previously published using the SFMHS sample set (Kothe et al. 2003) is shown for comparison.

Acknowledgements Chip Sheppard and Sean Watson of the California Department of Health Services for providing the HIVNET IPC specimens, without which this work would not have been possible. We would also like to thank Debra Kuehl, Silvina Masciotra, Hetal Patel, and Donna Rudolph for their help with organizing and aliquoting the IPC sample set